(CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
Open-label, 8 week study, to assess the efficacy and safety of oral Budesonide-MMX 9 mg
Extended-release Tablets in patients with mild to moderate, active ulcerative colitis who are
not in remission based on the Ulcerative Colitis Disease Activity Index in study CB-01-02/01
(parent study [NCT00679432]).
Phase:
Phase 3
Details
Lead Sponsor:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.